Category Archives: Ulcerative Colitis

June 25, 2020 08:00 ET | Source: Diversigen, Inc. ST. PAUL, Minn., June 25, 2020 (GLOBE NEWSWIRE) -- Diversigen, Inc., a subsidiary of OraSure Technologies Inc Continue reading →

Although there is genuine excitement surrounding Zeposia in the IBD community, there are several unknowns that still need to be resolved. Credit: Shutterstock + Emily frost Currently, in inflammatory bowel disease (IBD) there is an unmet need for novel oral drug formulations for patients with moderate-to-severe ulcerative colitis (UC) or Crohns disease (CD). Key opinion leaders (KOLs) interviewed by GlobalData in Q2 2020 believe that patients would prefer an oral formulation over the existing subcutaneously or intravenously delivered agents, as there is less concern surrounding immunogenicity and the route of administration is easier. Continue reading →

Eli Lilly and Co The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. Continue reading →

This Ulcerative Colitis Market report is prepared with the detailed market analysis performed by a team of industry experts, skilful analysts, dynamic forecasters and knowledgeable researchers. Continue reading →

Pfizer has linked with Nordic group SidekickHealth to launch a digital therapeutics platform designed to empower patients to take more control of their own health and boost wellbeing across Europe. According to the groups, scientific expertise and digital technologies have been combined to give patients a new tool to help them maintain healthy lifestyles and improve disease management and quality of life, while providing guidance and resources to facilitate communication with healthcare professionals. The platform focuses on a number of therapeutic areas Continue reading →

Inflammatory Bowel Disease Market report provide the COVID19 Outbreak Impact analysis of key factors influencing the growth of the market Size (Production, Value and Consumption). This Inflammatory Bowel Disease industry splits the breakdown (data status 2014-2020 and Six years forecast 2020-2026), by manufacturers, region, type and application. This study also analyses the Inflammatory Bowel Disease market Status, Market Share, Growth Rate, Future Trends, Market Drivers, Opportunities and Challenges, Risks and Entry Barriers, Sales Channels, Distributors and Porters Five Forces Analysis. Continue reading →

The high response rate of Neihulizumab in this study encourages us to move this drug candidate forward. SR-aGVHD continues to be a significant unmet medical need and further treatment options are required. Continue reading →

Infliximab and biosimilar Market Summary 2020-2025 Garner Insights released a new market study on Infliximab and biosimilar Market 2020 with industry data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand Detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Continue reading →

Eli Lilly and Co Ulcerative Colitis Market Competitive Landscape & Company Profiles Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Ulcerative Colitis market. Continue reading →

ST. LOUIS Zipping around the Texas Rangers spring training complex at Surprise Stadium just northwest of Phoenix, Kyle Gibson is miced up and heading to the players parking lot Continue reading →